Press Releases

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Kiniksa Announces Launch of ARCALYST Named Patient Program

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis

Kiniksa Outlines Next Steps for the Development of Mavrilimumab

Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404

Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients

Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis

Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis

Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity

Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones

Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis

Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404

Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis

Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020

Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis

Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data

Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

Kiniksa Announces Phase 2 Clinical Data from Vixarelimab in Prurigo Nodularis Presented at European Academy of Dermatology and Venereology Virtual Congress

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th

Kiniksa Announces Upcoming Rilonacept Analyst Day

Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis

Kiniksa Pharmaceuticals to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Kiniksa Presents Data on the Burden of Disease in Patients with Recurrent Pericarditis at the European Society of Cardiology Congress 2020

Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference

Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19

Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts

Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial

Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference

Kiniksa Announces Upcoming Presentation on Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation at the European E-Congress of Rheumatology 2020

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus

Kiniksa Reports First Quarter 2020 Financial Results and Highlights Recent Corporate and Pipeline Activity

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation

Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session

Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity

Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts

Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma

Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial

Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference

Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community

Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology

Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research

Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology

Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology

Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs

Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session

Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity

Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference

Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement

Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab

Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial

Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis

Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress

Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology

Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress

Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares

Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference

Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering

Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering

Kiniksa Pharmaceuticals to Present at 36th Annual J.P. Morgan Healthcare Conference

Sanj K. Patel to Introduce Kiniksa Pharmaceuticals at 35th Annual J.P. Morgan Healthcare Conference